Plasma is defined as a part of blood, which is a clear, straw-colored fluid residue after red platelets, white blood cells, blood cells, and other cellular components got eliminated. Human blood consists of various proteins. A mixture of lipoproteins, simple proteins, glycoproteins, and other conjugated proteins are called plasma proteins. By replacing the deficient or missing proteins in plasma, Plasma protein therapies are used to treat the well-defined medical condition. Plasma protein therapeutics include biological medicines, which are either infused or injected to treat life-threatening, chronic and genetic diseases. This plasma protein plays a vital role in blood clotting and also provides immunity against diseases.
Increasing usage of the plasma protein derived medicines worldwide; the introduction of new plasma-derived therapies is the major driving factors of the global plasma protein market. The market is also driven by a host of other factors, including the rising prevalence of life-threatening diseases of immune or neurological systems and infectious diseases like Rabies, Tetanus, Hepatitis A&B, and varicella. On the contrary, there are a few restraints for the market, which include stringent government policies, issues pertaining to reimbursement, complexity in manufacturing biologics, which may limit the growth of the market. With the technological advancements, the process involving fractionating the protein from plasma has become high-cost saving and efficient, which is also supposed to boost the global plasma protein therapeutics market. With increasing awareness among people about blood donations and government initiatives, the plasma-derived medicine market is expected to grow in the coming years at a significant rate.
The global plasma protein market is segmented on the basis of product type, which is further divided into coagulation factors, immunoglobulin, alpha-1 proteinase inhibitor, and albumin. Based on application, plasma protein therapeutics is segmented into idiopathic thrombocytopenic purpura, secondary immunodeficiency, hemophilia, hereditary angioedema, primary immunodeficiency disorder, and other indications. Based on geographical region, the market assessment is divided into the regions of North America, Asia-Pacific, Europe, Latin America, and Middle-East & Africa.
North America stood as a developed market for plasma protein therapeutic and is going to see quick growth in the future. Europe was one of the leading regional markets, followed by North America, and is expected to show significant growth in the years to come. In Europe, plasma protein therapeutics products are considered non-prescription products that allow their widespread use. Growth in the Asia Pacific plasma protein therapeutics market was expected to be driven by the increasing awareness about blood donations. In the Middle East & Africa region, the market is likely to register a modest growth rate due to a lack of awareness. Latin America is known to be an important regional market and is expected to experience sensible growth over the forecast period. Thus, all the above-stated improvements are going to push the market growth in the future.
C1 esterase inhibitor (Ruconest), Human glucocerebrosidase (Elelyso), VEGFR Fc-fusion (Eylea), CTLA-4 Fc-fusion (Nulojix), Anti-IL-6 receptor (Actemra), Anti-CD30 (Adcetris) are some of the U.S FDA approved therapeutic proteins that are produced by using different protein engineering technologies.
Some of the key players involved in the development of the global plasma protein market include Octapharma, LFB Group, Grifols, Baxter, CSL limited, Telecris, Kedrion, and Chengdu Inst; Japan Red Cross, BPL Group, Shanghai Blood Institute, and Sanquin are some of the nonprofit organizations, which also are playing an important role in the global plasma protein market.